Search This Blog

Tuesday, April 16, 2019

Organogenesis initiated at Oppenheimer

Oppenheimer starts ‘regenerative medicine story’ at Outperform. Oppenheimer analyst Steven Lichtman initiated coverage of Organogenesis with an Outperform rating and $11 price target. The company has a “diverse product set at different levels of complexity and price points that address a wide spectrum of wounds and musculoskeletal injuries,” Lichtman tells investors in a research note. The analyst sees Organogenesis’ markets as growing more than high-single digits and not highly penetrated. He calls the company as a “well-positioned regenerative medicine story.”

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.